These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26206619)

  • 1. Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.
    Athyros VG; Tziomalos K; Karagiannis A
    Expert Rev Cardiovasc Ther; 2015; 13(9):1059-66. PubMed ID: 26206619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
    Katsiki N; Mikhailidis DP; Banach M
    Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
    [No Abstract]   [Full Text] [Related]  

  • 3. Is lipid management effective for all stages of CKD?
    Ku E; Campese V
    Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyslipidemia as a therapeutic target for prevention of cardiovascular events and end-stage renal disease].
    Watanabe T
    Nihon Rinsho; 2008 Sep; 66(9):1761-9. PubMed ID: 18788407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
    Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Statins: what is their place in the treatment of chronic kidney insufficiency?].
    Ponte B; Bourquin V; Stoermann-Chopard C
    Rev Med Suisse; 2009 Feb; 5(192):463-4, 466-8. PubMed ID: 19317313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era.
    Heymann EP; Kassimatis TI; Goldsmith DJ
    J Nephrol; 2012; 25(4):460-72. PubMed ID: 22641572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
    Zuzda K; Grycuk W; Małyszko J; Małyszko J
    Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
    Scarpioni R; Ricardi M; Melfa L; Cristinelli L
    Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
    Campese VM
    Clin Exp Nephrol; 2014 Apr; 18(2):291-5. PubMed ID: 24535025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic kidney disease and statins].
    Matovinović MS
    Lijec Vjesn; 2006; 128(11-12):345-50. PubMed ID: 17212196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Expert Opin Pharmacother; 2015; 16(10):1449-61. PubMed ID: 26037614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statins in patients with chronic kidney disease: why, who and when?
    Gluba A; Rysz J; Banach M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2665-74. PubMed ID: 20977401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based statin prescription for cardiovascular protection in renal impairment.
    Fabbian F; De Giorgi A; Pala M; Tiseo R; Manfredini R; Portaluppi F
    Clin Exp Nephrol; 2011 Aug; 15(4):456-63. PubMed ID: 21556807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
    Kimura G; Kasahara M; Ueshima K; Tanaka S; Yasuno S; Fujimoto A; Sato T; Imamoto M; Kosugi S; Nakao K
    Clin Exp Nephrol; 2017 Jun; 21(3):417-424. PubMed ID: 27392909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of dyslipidemias in patients with diabetes and chronic kidney disease.
    Molitch ME
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1090-9. PubMed ID: 17699330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid lowering in liver and chronic kidney disease.
    Herrick C; Litvin M; Goldberg AC
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):339-52. PubMed ID: 24840263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease.
    Peev V; Nayer A; Contreras G
    Curr Opin Lipidol; 2014 Feb; 25(1):54-60. PubMed ID: 24345987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.